NCNA Key Statistics, Chart & Performance
The current stock price of NCNA is 4.28 USD. In the past month the price increased by 15.36%. In the past year, price decreased by -99.99%.
NCNA Latest News, Press Relases and Analysis
NCNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About NCNA
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 21
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What does NUCANA PLC-ADR do?
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Can you provide the latest stock price for NUCANA PLC-ADR?
The current stock price of NCNA is 4.28 USD. The price increased by 7.81% in the last trading session.
What is the dividend status of NUCANA PLC-ADR?
NCNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NCNA stock?
NCNA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of NCNA stock?
NUCANA PLC-ADR (NCNA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for NCNA stock?
NUCANA PLC-ADR (NCNA) currently has 21 employees.
NCNA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NCNA. When comparing the yearly performance of all stocks, NCNA is a bad performer in the overall market: 90.58% of all stocks are doing better.
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NCNA. While NCNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -286.47. The EPS increased by 98.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195.78% | ||
| ROE | -430% | ||
| Debt/Equity | 0.01 |